The PCA3 test is a new test based on DNA technology which provides a much more effective means of detecting prostate cancer than the standard PSA test.

Advances in medical technology have enabled scientists to detect miniscule processes within cells, such as the way genes express their coded information.

PCA3 is the expression of genes found in prostate cancer cells. Up to 100 times more PCA3 is present in prostate cancer cells than non-cancerous cells.

If a patient has a high proportion of PCA3, this can be detected in the patient’s urine.

The new urine test is combined with a rectal examination and a negative test can reassure patients and may help avoid the need for prostate biopsies. The result is known within days.

The new test will prevent many men from having unnecessary, repeated biopsies and indicate whether men are likely to have significant and aggressive prostate cancer.